Article Details
Retrieved on: 2024-08-07 21:20:42
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Neurogene Inc.'s NGN-401 receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating Rett syndrome, highlighting support programs that include accelerated approval pathways. This ties into the key concept of regenerative medicine and the tags related to FDA regulatory processes, gene therapy, and pharmaceutical policy.
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here